Fecal microbiota transplantation for the treatment of inflammatory bowel disease: an update
P Tan, X Li, J Shen, Q Feng - Frontiers in pharmacology, 2020 - frontiersin.org
P Tan, X Li, J Shen, Q Feng
Frontiers in pharmacology, 2020•frontiersin.orgFecal microbiota transplantation (FMT) has successfully been applied for the treatment of
recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to
other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota
dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD)
have been encouraging. However, studies have not fully clarified the clinical application of
this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing …
recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to
other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota
dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD)
have been encouraging. However, studies have not fully clarified the clinical application of
this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing …
Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients.
Frontiers以上显示的是最相近的搜索结果。 查看全部搜索结果